| Domain | Evidence-backed finding | Suggested ontology terms/IDs | Evidence caveat |
|---|---|---|---|
| Disease identity | Behr syndrome is a rare Mendelian syndromic optic neuropathy; Open Targets maps it to **MONDO:0008858** and associates it primarily with **OPA1** (pqac-00000000, pqac-00000001) | MONDO:0008858; OMIM:210000; MeSH/Orphanet/ICD IDs **curator verification needed** | MONDO/OPA1 support is strong, but external identifier crosswalks beyond MONDO/OMIM should be curator-checked |
| Nosology / synonymy | Current literature supports **OPA1-related Behr syndrome / Behr-related syndrome** for biallelic OPA1 disease; this should be **distinguished from OPA3-related Costeff syndrome**, which is a differential diagnosis rather than a true synonym (pqac-00000008, pqac-00000009) | Synonym candidate: “OPA1-related Behr syndrome”; Differential diagnosis: OPA3-related Costeff syndrome **(ontology ID curator verification needed)** | Historical literature used “Behr syndrome” broadly; modern molecular classification separates OPA1- from OPA3-related disease |
| Etiology / gene | The principal evidence-backed causal gene is **OPA1** (OPA1 mitochondrial dynamin like GTPase) (pqac-00000000, pqac-00000001, pqac-00000002) | HGNC:8156 **curator verification needed**; OPA1 | Evidence in retrieved contexts centers on OPA1; other historical “Behr-like” phenocopies are not excluded globally |
| Inheritance | Reported disease mechanism is **biallelic germline OPA1 pathogenic variants**, consistent with **autosomal recessive** inheritance in classic OPA1-related Behr syndrome (pqac-00000002, pqac-00000003, pqac-00000009) | Inheritance: autosomal recessive; Variant origin: germline | Some OPA1 disorders are dominant DOA/DOA+; inheritance must be tied specifically to the Behr syndrome subset |
| Core phenotype | Childhood/early-onset **optic atrophy** is the core presentation (pqac-00000002, pqac-00000003) | HPO: HP:0000648 optic atrophy | Frequency not well quantified in retrieved contexts |
| Core phenotype | **Spasticity / pyramidal signs / hyperreflexia** are characteristic neurologic features (pqac-00000002, pqac-00000014) | HPO: HP:0001257 spasticity; pyramidal signs **curator verification for exact HPO term** | Literature often groups pyramidal signs broadly; exact HPO mapping may need refinement |
| Core phenotype | **Ataxia / spinocerebellar degeneration** is a recurring major feature (pqac-00000002, pqac-00000003, pqac-00000009) | HPO: HP:0001251 ataxia | Cerebellar signs may include dysmetria/dysdiadochokinesis/nystagmus not fully decomposed here |
| Core phenotype | **Peripheral neuropathy** is repeatedly described (pqac-00000003, pqac-00000009) | HPO: HP:0009830 peripheral neuropathy | Subtype (axonal/sensory-motor) may vary and is not consistently specified in the retrieved contexts |
| Core phenotype | **Developmental delay** / delayed motor development can occur, especially in severe early-onset cases (pqac-00000002, pqac-00000003, pqac-00000009) | HPO: HP:0001263 developmental delay | Severity and domain specificity are variably reported |
| Associated phenotype | **Hearing impairment** / sensorineural deafness may occur (pqac-00000002, pqac-00000003, pqac-00000009) | HPO: HP:0000365 hearing impairment | Common in broader OPA1 syndromic disease, not necessarily present in all Behr syndrome cases |
| Associated phenotype | **Dysarthria** is reported among neurologic manifestations (pqac-00000002) | HPO: HP:0001260 dysarthria | Limited frequency data in retrieved contexts |
| Associated phenotype | **Dysphagia** and other gastrointestinal dysmotility features are described (pqac-00000002, pqac-00000003) | HPO: HP:0002015 dysphagia | GI findings may be underreported and are not universal |
| Associated phenotype | **Pes cavus** and contractures can occur (pqac-00000002) | HPO: HP:0001761 pes cavus | Musculoskeletal findings may overlap with neuropathy-related foot deformity |
| Imaging phenotype | Brain MRI may show **cerebellar atrophy**, including vermian atrophy (pqac-00000002, pqac-00000003, pqac-00000014) | HPO: HP:0001272 cerebellar atrophy | Exact HPO for vermian atrophy may be more specific; curator refinement may help |
| Anatomy / tissue | Major affected ocular cell type is the **retinal ganglion cell**; degeneration of RGCs underlies optic neuropathy (pqac-00000011, pqac-00000015, pqac-00000018) | CL:0000704 retinal ganglion cell **curator verification needed**; UBERON retina/retinal ganglion cell layer **curator verification needed** | Cell ontology ID should be verified before ingestion |
| Anatomy / organ | The **optic nerve** is a primary affected structure; optic nerve/chiasm atrophy is reported (pqac-00000002, pqac-00000014, pqac-00000015) | UBERON optic nerve **curator verification needed** | Chiasmal involvement may merit separate anatomical annotation |
| Anatomy / organ | The **cerebellum** is a major CNS site involved clinically and on MRI (pqac-00000002, pqac-00000014) | UBERON cerebellum **curator verification needed** | Vermis-specific annotation may be preferable when supported |
| Anatomy / system | **Corticospinal/pyramidal system** involvement is inferred from spasticity and hyperreflexia (pqac-00000002, pqac-00000014) | UBERON corticospinal tract / pyramidal tract **curator verification needed** | Structure-level assignment is phenotype-inferred rather than directly demonstrated in retrieved contexts |
| Anatomy / system | **Peripheral nerve** involvement is supported by neuropathy and contractures (pqac-00000003, pqac-00000014) | UBERON peripheral nerve **curator verification needed** | Specific nerves/cell subclasses were not defined in retrieved contexts |
| Molecular location | OPA1 is localized to the **mitochondrial inner membrane** (pqac-00000011, pqac-00000012, pqac-00000015) | GO:0005743 mitochondrial inner membrane | Strongly supported for OPA1 biology, but not unique to Behr syndrome |
| Biological process | A central upstream defect is impaired **mitochondrial inner membrane fusion** due to OPA1 dysfunction (pqac-00000011, pqac-00000015) | GO:0007342 mitochondrial inner membrane fusion | GO label/ID should be curator-verified in pipeline if strict ontology versioning is required |
| Cellular component | Abnormal **mitochondrial cristae** organization is repeatedly implicated (pqac-00000011, pqac-00000012, pqac-00000018) | GO: mitochondrial crista **ID curator verification needed** | Exact GO ID not supplied in retrieved contexts |
| Biological process | Downstream consequences include impaired **oxidative phosphorylation / respiratory function** (pqac-00000011, pqac-00000013) | GO: oxidative phosphorylation **ID curator verification needed** | Evidence is strong mechanistically but often derived from broader OPA1/AOA models rather than Behr-only cohorts |
| Biological process | OPA1 dysfunction is linked to defective **mtDNA maintenance / depletion** in severe disease (pqac-00000003, pqac-00000015) | GO: mitochondrial DNA maintenance **ID curator verification needed** | mtDNA depletion may be more prominent in severe or specific molecular contexts |
| Biological process | OPA1 participates in regulation of **apoptosis**, including cytochrome c release/cristae remodeling pathways (pqac-00000012, pqac-00000015, pqac-00000018) | GO: apoptosis **ID curator verification needed** | Much mechanistic evidence comes from OPA1 biology and model systems, not exclusively human Behr tissue |
| Biological process | Increased **mitophagy / autophagy** is a recurrent downstream mechanism in OPA1-deficient models (pqac-00000013, pqac-00000018) | GO: mitophagy **ID curator verification needed** | Model-system evidence stronger than direct human Behr syndrome tissue evidence |
| Diagnostics | Recommended workup in suspected hereditary optic neuropathy includes **next-generation sequencing**, with broader exome/genome testing for complex phenotypes; OPA1 diagnosis is established by identifying pathogenic variants (pqac-00000009, pqac-00000002) | MAXO: genetic testing **curator verification needed**; assay types: targeted panel / WES / WGS | Diagnostic strategy derives from hereditary optic neuropathy practice, not a Behr-specific guideline |
| Diagnostics | Ophthalmic and functional measures used in OPA1 trials include **BCVA/ETDRS**, visual fields/perimetry, color vision, contrast sensitivity, mfVEP, RNFL and GCL thickness by OCT (pqac-00000005, pqac-00000006, pqac-00000007) | MAXO: ophthalmologic examination; optical coherence tomography; visual field testing; visual evoked potentials **all curator verification needed** | Trial measures are from dominant OPA1 studies but remain relevant for phenotyping syndromic OPA1 disease |
| Management | No approved curative therapy is established; management is largely **supportive** (pqac-00000009) | MAXO: supportive care; rehabilitation; low-vision services **curator verification needed** | Statement reflects broader OPA1/DOA literature, not a dedicated Behr syndrome management guideline |
| Management | Practical supportive interventions may include **multidisciplinary rehabilitation** for gait/spasticity/neuropathy, speech therapy for dysarthria, swallowing support for dysphagia, audiology/hearing aids, and genetic counseling (pqac-00000002, pqac-00000009) | MAXO: physical therapy; occupational therapy; speech therapy; dysphagia management; hearing aid provision; genetic counseling **all curator verification needed** | These are evidence-informed generic interventions rather than trial-proven Behr-specific therapies |
| Recent development | 2024–2025 OPA1 interventional trials test **PYC-001**, an intravitreal peptide-phosphorodiamidate morpholino oligonucleotide, in **OPA1 haploinsufficiency-associated autosomal dominant optic atrophy**, not specifically Behr syndrome (pqac-00000004, pqac-00000005, pqac-00000006, pqac-00000007) | Clinical trials: NCT06461286; NCT06970106 | Important to avoid overgeneralizing these dominant OPA1 trial data to recessive OPA1 Behr syndrome |
| Differential diagnosis | Differential genetic diagnoses for optic atrophy-plus phenotypes include **OPA3**, **WFS1**, **MFN2**, **SPG7**, **AFG3L2**, **ACO2**, and others (pqac-00000008, pqac-00000009) | Disease/gene ontology entries **curator verification needed** | Differential list is not exhaustive and depends on presenting phenotype |
| Evidence source | Most information here is **aggregated disease-level literature/review evidence**, supplemented by Open Targets disease-gene association and OPA1 trial registry records, rather than EHR-derived patient aggregation (pqac-00000000, pqac-00000001, pqac-00000009) | Evidence categories: review, genetic association, clinical trial registry | Primary case-level extraction would still be needed for precise variant-phenotype curation |


*Table: This compact table summarizes ontology-ready facts for OPA1-related Behr syndrome, including identifiers, inheritance, phenotypes, anatomy, mechanisms, diagnostics, and supportive management. It also flags areas needing curator verification and clearly separates Behr syndrome from OPA3/Costeff syndrome.*